Risperidone for the Treatment of Huntington's Disease Involuntary Movements

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 13, 2020

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2023

Conditions
Huntington DiseaseChorea
Interventions
DRUG

Risperidone

capsule or tablet, 0.5 mg

DEVICE

BioStamp nPoint device

MC10 has developed the BioStamp nPointTM, a FDA 510(k) cleared medical device. This multimodal, reusable and rechargeable biosensor uses flexible and stretchable electronics to enable unobtrusive wear on the body and monitoring in the home. The sensors have accelerometry, gyroscopy, and ECG/EMG capabilities. A docking station enables wireless recharging and data collection.

Trial Locations (1)

14618

URMC Neurology; 919 Westfall Rd, Building C, Suite 100, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT04201834 - Risperidone for the Treatment of Huntington's Disease Involuntary Movements | Biotech Hunter | Biotech Hunter